Dr. Stephen Smith discusses advances in treatment for mantle cell lymphoma at ASH 2013. Dr. Smith feels this is a time of increased optimism for patients diagnosed with this rare and aggressive lymphoma that has historically been difficult to treat. Two new drugs were recently approved by the FDA. Revlimid (Lenalidomide) has been approved for patients having had two prior therapies, one including Bortezomib. Arutenib was given a breakthrough designation by the FDA based on its high clinical trial success, and is approved for patients having had one prior therapy. The challenge now is finding how to integrate these new therapies into current treatment regimens, and see results in real-world use that can differ slightly from clinical trials.